Which children could safely get less radiation? A tumor test offers a clue

A family dealing with a childhood brain tumor faces two different futures at once. Parents want the treatment most likely to keep the cancer from coming back. They also want to protect the child who will have to live with what that treatment does to memory and learning. A new Nature Genetics study offers a way to ask more precisely which children might benefit from less radiation. The researchers built MANTIS using tumor DNA methylation profiles from 2,786 patients across two diseases, medulloblastoma and ependymoma. Methylation marks are chemical tags on DNA; many centers already use the patterns to help classify brain tumors. MANTIS uses those data to estimate an individual survival curve over ten years. The medulloblastoma model was validated in three separate clinical-trial cohorts totaling 898 patients. That is a test against real follow-up data, not a trial in which a model chose a child’s treatment. The team then revisited radiation doses for average-risk medulloblastoma. Its analysis singled out roughly 60% of the patients studied in that setting as possible candidates for lower-dose radiation to the brain and spine. The researchers did not detect a statistically significant survival disadvantage in that selected group; lower doses were associated with better cognitive outcomes. A difference too small to detect in one analysis can still matter enormously to a child. The promising result is a testable way to select patients for a trial, not evidence that six in ten children receiving cancer care should have treatment reduced.